Shares of Endo International PLC (NASDAQ:ENDP) have received an average recommendation of “Hold” from the twenty-four research firms that are presently covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a sell recommendation, fifteen have given a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $16.73.

Several equities research analysts have commented on ENDP shares. Mizuho reissued a “buy” rating and set a $18.00 price target (up from $17.00) on shares of Endo International PLC in a research report on Thursday, April 13th. Zacks Investment Research raised shares of Endo International PLC from a “sell” rating to a “hold” rating in a research report on Tuesday, May 2nd. Canaccord Genuity set a $14.00 price target on shares of Endo International PLC and gave the stock a “hold” rating in a research report on Monday, May 1st. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Endo International PLC in a research report on Sunday, July 23rd. Finally, Deutsche Bank AG cut their price target on shares of Endo International PLC from $18.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, July 7th.

WARNING: “Endo International PLC (ENDP) Given Average Recommendation of “Hold” by Brokerages” was published by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/08/08/endo-international-plc-endp-given-average-recommendation-of-hold-by-brokerages.html.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Icon Advisers Inc. Co. boosted its position in Endo International PLC by 314.4% in the first quarter. Icon Advisers Inc. Co. now owns 74,600 shares of the company’s stock valued at $833,000 after buying an additional 56,600 shares in the last quarter. Comerica Bank boosted its position in Endo International PLC by 233.7% in the first quarter. Comerica Bank now owns 153,881 shares of the company’s stock valued at $1,736,000 after buying an additional 107,761 shares in the last quarter. Bank of New York Mellon Corp boosted its position in Endo International PLC by 38.7% in the first quarter. Bank of New York Mellon Corp now owns 2,271,111 shares of the company’s stock valued at $25,345,000 after buying an additional 633,904 shares in the last quarter. Point View Wealth Management Inc. boosted its position in Endo International PLC by 12.3% in the first quarter. Point View Wealth Management Inc. now owns 11,431 shares of the company’s stock valued at $128,000 after buying an additional 1,254 shares in the last quarter. Finally, Capital Fund Management S.A. bought a new position in Endo International PLC during the first quarter valued at $260,000. 93.00% of the stock is currently owned by hedge funds and other institutional investors.

Endo International PLC (NASDAQ:ENDP) traded down 12.14% during mid-day trading on Tuesday, hitting $8.18. The stock had a trading volume of 22,056,417 shares. Endo International PLC has a 1-year low of $8.15 and a 1-year high of $24.93. The company has a 50-day moving average price of $11.45 and a 200 day moving average price of $11.76. The company’s market cap is $1.83 billion.

Endo International PLC (NASDAQ:ENDP) last issued its quarterly earnings results on Tuesday, August 8th. The company reported $0.93 EPS for the quarter, topping the consensus estimate of $0.74 by $0.19. Endo International PLC had a negative net margin of 82.93% and a positive return on equity of 25.32%. The firm had revenue of $875.73 million for the quarter, compared to analysts’ expectations of $832.66 million. During the same period in the previous year, the firm posted $0.86 EPS. The company’s revenue for the quarter was down 4.9% on a year-over-year basis. Equities research analysts forecast that Endo International PLC will post $3.53 EPS for the current fiscal year.

Endo International PLC Company Profile

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Analyst Recommendations for Endo International PLC (NASDAQ:ENDP)

Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.